In our study, no decrease in the CD56+ T cell proportion was observed in COVID-19; nevertheless, those patients who survived after the admission to the ICU had a higher proportion of CD56+ cells, suggesting that this factor has a prognostic significance in the severe group (Figure 2e). Here, NCAM1 is linked to COVID-19.